Purpose: This cohort aimed to evaluate the safety and efficacy outcomes of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) in a Western Australia tertiary hospital, Royal Perth Hospital (RPH), and potential associations between age, gender, tumour size, location, chronic kidney disease, comorbidities and local recurrence against existing benchmarks.
Methods: We retrospectively analysed survival outcomes for patients with biopsy proven RCC treated by RFA at Royal Perth Hospital between 2009 and 2018. Complication data were gathered for all patients that underwent renal RFA along with 2- and 5-year recurrence-free (RFS) and compared the outcomes with data from previous studies. I confirm that all methods were carried out in accordance with relevant guidelines and regulations.
Results: A total of 69 patients (73 procedures) were eligible for the study with biopsy-proven RCC had minimum 2-year follow-up. The RPH complication rate was 8.2 % (6/73) and local recurrence rate 10.9 % (8/73). Two-year RFS is 95.6% and Five-year RFS is 78.78% on a median 3.82-year follow-up (IQR 1.9-5.75).
Conclusion: Radiofrequency ablation performed at our centre was found to be safe and effective with low complication rates and durable RFS in line with expectations from existing research. Our study demonstrated that radiofrequency ablation is an alternative modality of treatment for small renal tumours in patients unfit for surgical approach.